The team behind UK-designed sleep therapy solution SleepCogni is celebrating after their device produced ‘extraordinary’ clinical trial results, significantly reducing clinical insomnia after just seven days. Following the successful trials, conducted at Sheffield Hallam University with a group of 80 people suffering from chronic insomnia, the device is now primed to be launched on to the global $80bn sleep aid market.
SleepCogni is an easy to use hand-held sleeping aid which helps insomnia sufferers break cognitive cycles that prevent sleep. Co-founded by Sheffield-based entrepreneur Richard Mills, who has personally suffered from sleeping disorders, and Dutch chronobiologist and sleep expert, Dr Maan van de Werken, the device enables users to self-manage their insomnia, a condition which affects one in three people across the world.
During its clinical trial the device was found to significantly reduce participants’ clinical level of insomnia to non-clinical levels in just seven days, with a substantially faster reduction achieved on the Insomnia Severity Index than typically seen with other forms of treatment. Many of those who took part reported how SleepCogni helped them control their thoughts at bedtime and fall asleep more easily with some claiming they experienced their ‘best sleep in years’ when using the device. There was also strong feedback from trial participants that it addressed their condition better than any other remedy they’d previously tried.
The successful trials follow the device’s registration with the Food and Drug Administration (FDA), announced earlier this month, opening up immediate access to an estimated 70m sleep sufferers living in the US. SleepCogni is now about to embark on a new investment round to help build its brand in the US and across other global markets.
The company’s team of advisers is comprised of some of the most highly respected figures from the global healthcare sector. This includes SleepCogni’s chairman Richard di Benedetto, President of Aetna International health insurance.
Dr Maan van de Werken, SleepCogni’s co-founder and CSO said: “We’re hugely encouraged by the results from our largest trial to date, with 80 participants suffering from chronic insomnia taking part. The user feedback was outstanding and the reduction of insomnia complaints recorded in the patients that used our device was substantial. It is especially noteworthy that we saw these benefits on such a short timescale, within a week of using our self-administered device.”
SleepCogni co-founder and CEO, Richard Mills, said: “The success of the clinical trials marks another important step forward in SleepCogni’s progress. These outstanding results, combined with FDA registration give us positive momentum as we seek to develop our brand across global markets, including the US.”
The clinical trials were led by Dr Antonia Ypsilanti, Associate Professor of Cognitive Psychology and Dr Lambros Lazuras, Associate Professor in Social Psychology at Sheffield Hallam University. Dr Ypsilanti said: “The SleepCogni trials produced extraordinary results, reducing clinical insomnia to subthreshold insomnia in just seven days for those using the device. It’s ground-breaking to see such a drastic improvement on insomnia severity, and unsurprising to hear participants commenting how the device helped them relax and gain control of their sleep with many claiming it was better than any other sleep improvement approaches they’d used in the past.”